An FDA-Approved Option for a Use Its Own Trials Never Tested
A single patient stable for years on a compounded regimen her insurer now wants replaced with the newly approved version of the same drug class. The disagreement is whether 'approved' means 'better evidenced' for the specific thing she actually needs it for.
Grace H. has been symptom-free for three years on a compounded viscous budesonide suspension her gastroenterologist built specifically for her — budesonide respules mixed with sucralose to a consistency that clings to the esophagus long enough to work, a formulation with no formal FDA approval but a long, well-documented off-label track record in exactly this disease. Her insurer's annual formulary review just flagged that compounded product for prior authorization, pointing instead to Eohilia, the budesonide oral suspension the FDA approved in 2024 as the first dedicated oral therapy for eosinophilic esophagitis — a real, approved product with real trial data behind it, and the obvious-sounding preference for a formulary committee weighing manufacturing consistency against a compounded alternative.
The complication that formulary logic misses is what Eohilia's own trials actually tested. Both pivotal studies ran twelve weeks, and the product's own label carries a limitation of use stating it hasn't been shown safe or effective beyond that duration — a real, stated boundary, not an oversight. Grace doesn't need a twelve-week course; she needs the multi-year maintenance regimen that's already kept her in remission for three years, a use case Eohilia's approval was never built to address. "FDA-approved" and "better evidenced for what this particular patient actually needs" are being treated as the same claim by the people making the formulary decision, and for Grace specifically, they aren't.
Grace's own account of the years before her current regimen adds weight to why continuity matters here beyond simple inertia. She cycled through an unrestricted diet, then a six-food elimination attempt she couldn't sustain around a demanding work schedule, before her gastroenterologist built the compounded regimen that finally worked — three failed or abandoned approaches before landing on the one that's kept her symptom-free for three straight years. A formulary switch that looks, on paper, like a lateral move between two formulations of the same drug reads very differently to a patient who remembers exactly how long it took to get here.
An approval that doesn't cover her actual use case
I'd keep Grace on her compounded regimen and appeal this directly. Eohilia's own label limits its studied use to twelve weeks — it says so explicitly, not treated beyond that duration in either pivotal trial. Grace needs multi-year maintenance. The approved product simply hasn't been tested for the thing she actually requires.
I want to name a real concern the label point doesn't address: compounded corticosteroids carry documented variability in potency and delivery consistency between pharmacies and even between batches from the same one. That's a genuine quality issue independent of what any trial did or didn't test.
I’m not disputing what the label says about study duration. I’m saying "the trial didn’t run long enough" and "the compounded version is manufactured reliably" are two separate questions, and settling the first one in her favor doesn’t settle the second.
Both of those points are real, and I think they answer different situations. If Grace were starting therapy today, treatment-naive, I'd take the manufacturing-consistency argument seriously as a reason to start with the approved product, label-duration gap aside.
But she isn't starting today. She has three years of her own biopsy results proving a specific compounded formulation works for her. That's patient-specific evidence a general formulary preference doesn't override, and I don't think continuity of something already proven should be disrupted on a policy default built for patients who haven't already answered this question.
Agreed: continue the compounded regimen, and submit a formal appeal to the insurer documenting the approved product's twelve-week trial duration and label limitation against her three-year maintenance need.
Not fully agreed on the general policy question underneath this specific case:
The clinical pharmacologist would default to the approved product first, given the real manufacturing-consistency argument, label-duration gap notwithstanding.
The gastroenterologist would want the label gap disclosed to any new patient explicitly before defaulting to it, rather than treating 'approved' as a silent proxy for 'best evidenced for long-term use.'
Grace's own plan is settled. What the team would tell the next patient walking in treatment-naive is not — that conversation was flagged as worth having on its own, separately.